Literature DB >> 22293555

2011 FDA drug approvals.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22293555     DOI： 10.1038/nrd3657

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  38 in total

1.  Positive signals from Washington.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

Review 2.  Challenges in sexual medicine.

Authors:  Selim Cellek; Annamaria Giraldi
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 4.  Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting.

Authors:  Muhammad Abdur Rahim; Nasrullah Jan; Safiullah Khan; Hassan Shah; Asadullah Madni; Arshad Khan; Abdul Jabar; Shahzeb Khan; Abdelbary Elhissi; Zahid Hussain; Heather C Aziz; Muhammad Sohail; Mirazam Khan; Hnin Ei Thu
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

5.  The predicated demise of racemic new molecular entities is an exaggeration.

Authors:  Israel Agranat; Silvya R Wainschtein; Enav Z Zusman
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

6.  Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file.

Authors:  Andrew S Bell; Joseph Bradley; Jeremy R Everett; Michelle Knight; Jens Loesel; John Mathias; David McLoughlin; James Mills; Robert E Sharp; Christine Williams; Terence P Wood
Journal:  Mol Divers       Date:  2013-04-05       Impact factor: 2.943

Review 7.  Contributions from emerging transcriptomics technologies and computational strategies for drug discovery.

Authors:  Onat Kadioglu; Thomas Efferth
Journal:  Invest New Drugs       Date:  2014-03-16       Impact factor: 3.850

Review 8.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

9.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

10.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.